OPT101 in Type 1 Diabetes Patients

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 27, 2022

Primary Completion Date

February 21, 2024

Study Completion Date

February 21, 2024

Conditions

Diabetes Mellitus, Type 1

Interventions

DRUG

OPT101

15-mer peptide derived from the sequence of mouse CD154.

Trial Locations (2)

Diablo Clinical Research Center, Walnut Creek

Rainier Clinical Research Center, Renton

All Listed Sponsors

lead

Op-T LLC

INDUSTRY